PDS Biotechnology Corp (PDSB) Financials

$0.31

$0.09 (40.32%)

As on 08-Sep-2026 12:38EDT

Market cap

$12 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

3.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.02	0.06	0.06	0.06	0.05	0.25
Gross Profit	-0.02	-0.06	-0.06	-0.06	-0.05	-0.25
Operating Expenses	27.83	31.54	36.26	43.05	41.67	21.44
Operating Profit (EBIT)	-27.83	-31.54	-36.32	-43.05	-41.67	-21.44
Other Income	--	--	--	--	--	--
Profit before Tax	-33.67	-35.67	-38.48	-44.35	-42.05	-21.43
Provision for Tax	2.34	-1.17	-0.87	-1.41	-1.20	-4.52
Profit after Tax (Net Income)	-33.67	-34.50	-37.61	-42.94	-40.85	-16.92
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-40.85	-16.92

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	-3.58	9.25	19.00	26.13	44.00	63.21
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.01	11.76	9.27	19.63	23.18	0.23
Current Liabilities	12.38	9.48	17.09	13.63	9.82	3.76
Total Liabilities	21.18	30.49	45.36	59.39	77.01	67.20

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	1.76	2.24	0.30	0.34	0.53	0.36
Current Assets	7.05	28.25	45.05	59.06	76.48	66.84
Total Assets	21.18	30.49	45.36	59.39	77.01	67.20
Total Debt*	4.36	16.93	21.83	23.85	23.47	0.49
Net Current Assets	-5.33	18.77	27.97	45.43	66.66	63.08

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-27.75	-35.03	-33.64	-25.71	-12.49
Cash Flow from Investing Activities	--	--	-0.03	--	--	--
Cash from Financing Activities	--	12.77	20.19	16.38	34.29	48.89
Net Cash Inflow / Outflow	--	--	--	--	8.58	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.66	-0.74	-1.03	-1.36	-1.42	-0.60
Cash EPS ($)	--	-0.74	-1.03	-1.36	-1.42	-0.59
Adjusted Book Value ($)	--	0.20	0.52	0.83	1.53	2.22
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.60	-0.96	-1.06	-0.89	-0.44
Free Cash Flow per Share ($)	--	-0.60	-0.96	-1.06	-0.89	-0.44

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-102.96	-82.83	-73.12	-62.29	-37.00
ROE (%)	--	-244.16	-166.65	-122.46	-76.21	-37.46
ROA (%)	-92.01	-90.95	-71.81	-62.97	-56.66	-34.50
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	55.82	10.29	15.78	1.46	-90.05	-43.84
Net Profit Growth (%)	8.01	8.28	12.42	-5.11	-141.48	-13.95
EPS Growth (%)	28.31	0.28	0.24	0.05	-1.39	0.11
Book Value Growth (%)	-118.50	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-1.04	-1.58	-3.67	-9.29	-13.61
Price / Book Value	3.47	3.86	3.13	6.02	8.63	3.64
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-2.58	-0.86	-1.17	-3.11	-8.09	-7.72
Close Price ($)	0.88	0.77	1.63	4.97	13.20	8.10
High Price ($)	1.55	2.20	6.68	13.65	13.65	17.85
Low Price ($)	0.51	0.70	1.53	3.80	2.89	2.13
Market Cap ($ Cr)	12.31	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	1.83	1.15	0.91	0.53	0.01
Short term debt to equity ratio	-1.22	0.56	0.66	0.16	0.01	0.00
Current Ratio	0.57	2.98	2.64	4.33	7.79	17.80
Quick Ratio	0.57	--	--	--	--	--
Interest Coverage	-4.06	-5.68	-7.23	-9.54	-30.93	-4,932.11

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	15,871.02	26,474.51	26,129.69	9,409.55	2,019.52
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.